Kizilisik A Tarik, Ray Jacqueline M, Nylander William A, Langone Anthony J, Helderman J Harold, Shaffer David
Veterans Administration Medical Center, 1310 26th Ave. S., Nashville, TN 37212, USA.
Am J Surg. 2004 Nov;188(5):611-3. doi: 10.1016/j.amjsurg.2004.07.022.
A shortage of organ donors remains the major limiting factor in kidney transplantation. Living donor renal transplantation, especially living-unrelated donors, may expand the donor pool by providing another source of excellent grafts.
Between 1983 and 2003, 109 living donor kidney transplants were performed. Potential donors were assessed with a standardized routine. Antithymocyte serum (N-ATS) and Basiliximab were used as induction agents. Sandimmune, Gengraf, Neoral, and Prograf were the main immunosuppressants with Immuran, Mycophenolate Mofetil, and steroids. Eighty-two percent of the recipients were from out of state.
Seventy-eight percent of the living donors were from living-related donors and 22% were from living-unrelated donors. One- and three-year patient survival rates were 97.6% and 93.2% with 1- and 3-year graft survival rates of 93.2% and 88.3%, respectively. There were 6 delayed graft functions (5.5%), 16 acute cellular rejections (10%), and 10 chronic rejections (9%). Twelve patients died, 7 of them with a functioning graft. In the past 6 years (1997-2003), the number of living donor kidney transplants surpassed deceased donor kidney transplants.
Because of the limited number of cadaveric kidneys available for transplant, living donors represent a valuable source, and the use of living-unrelated donors has produced an additional supply of organs. In our program, the proportion of living donors used for kidney transplant is comparable with other non-Veterans Administration programs and the survival of these allografts appears to be superior to deceased donor kidney transplants.
器官供体短缺仍然是肾移植的主要限制因素。活体供肾移植,尤其是非亲属活体供肾移植,可通过提供另一种优质移植物来源来扩大供体库。
1983年至2003年间,共进行了109例活体供肾移植。对潜在供体进行标准化常规评估。使用抗胸腺细胞血清(N-ATS)和巴利昔单抗作为诱导剂。环孢素、他克莫司、新山地明和普乐可复是主要的免疫抑制剂,同时使用硫唑嘌呤、霉酚酸酯和类固醇。82% 的受者来自外州。
78% 的活体供体为亲属活体供体,22% 为非亲属活体供体。1年和3年的患者生存率分别为97.6% 和93.2%,1年和3年的移植物生存率分别为93.2% 和88.3%。有6例移植肾功能延迟恢复(5.5%),16例急性细胞排斥反应(10%),10例慢性排斥反应(9%)。12例患者死亡,其中7例移植物仍有功能。在过去6年(1997 - 2003年)中,活体供肾移植的数量超过了尸体供肾移植。
由于可用于移植的尸体肾数量有限,活体供体是一个宝贵的来源,非亲属活体供体的使用增加了器官供应。在我们的项目中,用于肾移植的活体供体比例与其他非退伍军人管理局项目相当,并且这些同种异体移植物的存活率似乎优于尸体供肾移植。